In a much-anticipated press conference Thursday, President Donald Trump said the U.S. has stepped up near-term efforts to advance and make available antivirals to help patients with COVID-19 illnesses.
But despite the urgency and the progress, FDA commissioner Stephen Hahn said it’s important to learn more about all potential treatments.
Amid the pandemic, one drug that’s gained attention in various countries is chloroquine, a decades-old malaria med that’s available for cheap. President Trump said the U.S. is going to make the drug available by prescription “almost immediately.”
Chloroquine is already approved to treat malaria, and Hahn said investigators are planning a “large, pragmatic clinical trial” to learn more. But, the commissioner cautioned, it’s always important to get the “right drug” to the “right patient” at the “right dosage” at the “right time.” The wrong dose could actually hurt a patient’s condition, he added.
While chloroquine isn’t approved for patients with novel coronavirus infections, Trump may have been referencing an off-label use for the medicine. It wasn’t immediately clear how the drug would become available imminently.
Aside from chloroquine, the president and FDA commissioner Hahn talked about efforts to test Gilead’s remdesivir, originally developed for Ebola. Trump said that drug is “very close to approved,” but Hahn declined to specify potential approval timelines.
Coronavirus tracker: Merck CEO calls on Americans to limit contact; FDA halts domestic inspections
Other efforts are underway for plasma-based therapies and repurposing existing medicines, Hahn said at the press conference.
Meanwhile, investigators have launched a vaccine trial “in record time,” the president said. It’ll be 12 months before the study completes and the FDA could potentially approve the shot, Hahn said.
Until then, the antivirals and other drugs are intended to be a “bridge” for treatment until the medical community has a deployable vaccine, Hahn added.
By Eric Sagonowsky
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
